Management of Diarrhea in Breast Cancer

Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses patient conversations regarding extended adjuvant therapy with neratinib (Nerlynx) in early-stage HER2-positive breast cancer.

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

Lauren Nye, MD, discusses the promise of neratinib in patients with early HER2-positive breast cancer, as well as ways to ease concern of associated toxicity.

Extended adjuvant treatment with neratinib given with or without antidiarrheal prophylaxis was associated with decreases in health-related quality of life in patients with HER2-positive breast cancer.

Michel Velez, MD, addresses how loperamide and other methods of prophylaxis are significantly reducing the risk of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).

Martin Dietrich, MD, PhD, discusses ways of offsetting neratinib-associated diarrhea for patients with early-stage HER2-positive breast cancer at high risk of recurrence in need of extended adjuvant therapy.

A loperamide prophylactic regimen with or without the addition of either budesonide or colestipol in patients with HER2-positive early breast cancer who received treatment with neratinib (Nerlynx) led to a significant reduction in incidence and severity of diarrhea.